Primary Site >> Liver Cancer

Gene >> LAPTM4B

  • 2000
  • 2003
  • 2004
  • 2005
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2016
  • 2017
  • 2018
Ref: Biological function of a novel gene overexpressed in human hepatocellular carcinoma.
PMID: 11775832
Ref: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma.
PMID: 12902989
Ref: [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene].
PMID: 12947545
Ref: Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma.
PMID: 15162524
Ref: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
PMID: 15884107
Ref: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression.
PMID: 15911104
Ref: Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
PMID: 15994756
Ref: Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer.
PMID: 17074969
Ref: Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma.
PMID: 17276673
Ref: Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers.
PMID: 17965115
Ref: Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma.
PMID: 18334282
Ref: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells.
PMID: 19843073
Ref: LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
PMID: 19690886
Ref: Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.
PMID: 20202745
Ref: LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
PMID: 20358632
Ref: Highly specific targeting and imaging of live cancer cells by using a peptide probe developed from rationally designed peptides.
PMID: 21542089
Ref: Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line.
PMID: 21618708
Ref: Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
PMID: 21626328
Ref: Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer.
PMID: 22156622
Ref: Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients.
PMID: 22207410
Ref: LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.
PMID: 22509374
Ref: Targeting a novel cancer-driving protein (LAPTM4B-35) by a small molecule (ETS) to inhibit cancer growth and metastasis.
PMID: 27542271
Ref: Correlation of lysosome-associated protein transmembrane-4beta gene overexpression with the malignant phenotypes of hepatocellular carcinoma.
PMID: 29108920
Ref: Long Noncoding RNA HCAL Facilitates the Growth and Metastasis of Hepatocellular Carcinoma by Acting as a ceRNA of LAPTM4B.
PMID: 29246322
Ref: AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity.
PMID: 29337428
Ref: Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.
PMID: 29882487